

115TH CONGRESS  
1ST SESSION

# H. R. 1660

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 21, 2017

Mr. STRES (for himself, Mr. DIAZ-BALART, Mr. CONNOLLY, Mr. ENGEL, Mr. SHERMAN, Mr. CICILLINE, Mr. KEATING, Ms. ROS-LEHTINEN, Mr. DONOVAN, and Mr. SMITH of New Jersey) introduced the following bill; which was referred to the Committee on Foreign Affairs

---

## A BILL

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Global Health Innova-  
5 tion Act of 2017”.

1 **SEC. 2. ANNUAL REPORT.**

2 (a) IN GENERAL.—Not later than 180 days after the  
3 date of the enactment of this Act, and annually thereafter  
4 for a period of 4 years, the Administrator of the United  
5 States Agency for International Development shall submit  
6 to Congress a report on the development and use of global  
7 health innovations in the programs, projects, and activities  
8 of the Agency.

9 (b) MATTERS TO BE INCLUDED.—The report re-  
10 quired by subsection (a) shall include the following:

11 (1) A description of—

12 (A) the extent to which global health inno-  
13 vations described in subsection (a) include  
14 drugs, diagnostics, devices, vaccines, electronic  
15 and mobile health technologies, and related be-  
16 havior change and service delivery innovations;

17 (B) how innovation has advanced the  
18 Agency's commitments to achieving an HIV/  
19 AIDS-free generation, ending preventable child  
20 and maternal deaths, and protecting commu-  
21 nities from infectious diseases, as well as  
22 furthered by the Global Health Strategic  
23 Framework;

24 (C) how goals are set for health product  
25 development in relation to the Agency's health-

1 related goals and how progress and impact are  
2 measured towards those goals;

3 (D) how the Agency's investments in inno-  
4 vation relate to its stated goals; and

5 (E) progress made towards health product  
6 development goals.

7 (2) How the Agency, both independently and  
8 with partners, donors, and public-private partner-  
9 ships, is—

10 (A) leveraging United States investments  
11 to achieve greater impact in health innovation;

12 (B) engaging in activities to develop, ad-  
13 vance, and introduce affordable, available, and  
14 appropriate global health products; and

15 (C) scaling up appropriate health innova-  
16 tions in the development pipeline.

17 (3) A description of collaboration and coordina-  
18 tion with other Federal departments and agencies,  
19 including the Centers for Disease Control and Pre-  
20 vention, in support of global health product develop-  
21 ment, including a description of how the Agency is  
22 working to ensure critical gaps in product develop-  
23 ment for global health are being filled.

24 (4) A description of how the Agency is coordi-  
25 nating and aligning global health innovation activi-

1 ties between the Global Development Lab, the Cen-  
2 ter for Accelerating Innovation and Impact, and the  
3 Bureau for Global Health.

